Byondis, based in Nijmegen, the Netherlands, is developing a pipeline of precision medicines targeting intractable cancers and autoimmune diseases. Byondis began life as Synthon Biopharmaceuticals ...

Byondis, headquartered in Nijmegen, the Netherlands, has many years of experience in antibody–drug conjugation, targeted cytotoxic therapy and linker-drug technology, along with in-house good ...

Byondis has filed its HER2-targeting antibody-drug conjugate (ADC) trastuzumab duocarmazine in the US and Europe, setting up possible approvals next year and a showdown with heavyweight ...